Real-World experience of interictal burden and treatment in migraine: a qualitative interview study

被引:16
|
作者
Lo, Siu Hing [1 ]
Gallop, Katy [1 ]
Smith, Timothy [2 ]
Powell, Lauren [3 ]
Johnston, Karissa [3 ]
Hubig, Lena T. [1 ]
Williams, Emma [1 ]
Coric, Vladimir [4 ]
Harris, Linda [4 ]
L'Italien, Gilbert [4 ]
Lloyd, Andrew J. [1 ]
机构
[1] Acaster Lloyd Consulting Ltd, 8th Floor,Lacon House,84Theobalds Rd, London WC1X 8NL, England
[2] StudyMetrix Res LLC, 3862 Mexico Rd, St Peters, MO 63303 USA
[3] Broadst HEOR, 201-343 Railway St, Vancouver, BC V6A 1A4, Canada
[4] Biohaven Pharmaceut Inc, 215 Church St, New Haven, CT 06510 USA
来源
JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / 01期
关键词
Migraine; Interictal burden; Health-related quality of life; Treatment experience; Qualitative;
D O I
10.1186/s10194-022-01429-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The debilitating nature of migraine attacks is widely established; however, less is known about how the interictal burden (i.e., how patients are affected in-between migraine episodes) of migraine impacts on patients' health-related quality of life (HRQL). Acute and preventive treatments may lift the burden of the disease, but they often have unwanted side effects and limited effectiveness. The objective of this study was to understand the interictal burden of migraines, from the patient perspective, and to explore patient experience with migraine treatments. Methods Participants (n=35) with a self-reported diagnosis of migraine were recruited in the US, UK and Canada, including a subgroup of patients who had taken calcitonin gene-related peptide monoclonal antibody (CGRP mAb) treatment for at least three months. Participants completed a background questionnaire, followed by a semi-structured interview via telephone or video call. The interviews explored patients' migraine symptoms, perception of interictal burden and treatment experience. The interview transcripts were analysed using thematic analysis. Results The most reported migraine symptom was migraine pain, followed by aura, sensory sensitivity and nausea. Most participants reported interictal impact on HRQL, lifestyle changes they made to avoid triggers or in anticipation of an attack, impacts on work, career, daily activities and relationships. Emotional impacts were reported by all participants, including anger, depression, anxiety and hopelessness. Many participants who took preventive treatments reported improvements in HRQL and functioning but still experienced breakthrough attacks. Among patients who took CGRP mAbs, participants noted varying consistency of treatment effectiveness between treatment administrations. Conclusion This study detailed the additional HRQL impact of migraine in-between migraine attacks and described the unmet need for effective treatment options to prevent and mitigate migraine attacks.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Galcanezumab in the Treatment of Migraine: A Narrative Review of Real-World Studies
    Dell Agnello, Grazia
    Buzzoni, Carlotta
    Antenori, Amalia
    Torelli, Federico
    Altamura, Claudia
    Vernieri, Fabrizio
    CLINICAL NEUROPHARMACOLOGY, 2023, 46 (06) : 220 - 228
  • [42] A Real-World Study of the Patient Experience of Osteoporosis Following Treatment with Abaloparatide
    Gold, Deborah T.
    Weiss, Rich
    Wang, Yamei
    Williams, Setareh
    Roberts, Jenna
    Bailey, Tom
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 260 - 260
  • [43] Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients
    Kwon, Soonwook
    Gil, Young-Eun
    Lee, Mi Ji
    CEPHALALGIA, 2022, 42 (08) : 705 - 714
  • [44] Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
    Silvestro, Marcello
    Tessitore, Alessandro
    Orologio, Ilaria
    De Micco, Rosa
    Tartaglione, Lorenzo
    Trojsi, Francesca
    Tedeschi, Gioacchino
    Russo, Antonio
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [45] Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience
    Marcello Silvestro
    Alessandro Tessitore
    Ilaria Orologio
    Rosa De Micco
    Lorenzo Tartaglione
    Francesca Trojsi
    Gioacchino Tedeschi
    Antonio Russo
    The Journal of Headache and Pain, 2022, 23
  • [46] Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain
    Patricia Pozo-Rosich
    Mafalda Carmo
    Alejandro Muñiz
    Beatriz Armada
    Carlota Moya-Alarcón
    Julio Pascual
    BMC Neurology, 24
  • [47] Topiramate vs Divalproex Sodium in the Preventive Treatment of Migraine: A Prospective "Real-World" Study
    Krymchantowski, Abouch V.
    Jevoux, Carla C.
    HEADACHE, 2011, 51 (04): : 554 - 558
  • [48] Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
    Pozo-Rosich, Patricia
    Lucas, Christian
    Watson, David P. B.
    Gaul, Charly
    Ramsden, Emma
    Ritter, Shannon
    Martelletti, Paolo
    Snellman, Josefin
    PAIN AND THERAPY, 2021, 10 (02) : 1691 - 1708
  • [49] Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
    Patricia Pozo-Rosich
    Christian Lucas
    David P. B. Watson
    Charly Gaul
    Emma Ramsden
    Shannon Ritter
    Paolo Martelletti
    Josefin Snellman
    Pain and Therapy, 2021, 10 : 1691 - 1708
  • [50] A REAL-WORLD STUDY OF THE PATIENT EXPERIENCE WITH ABALOPARATIDE
    Gold, D. T.
    Weiss, R. J.
    Roberts, J.
    Bailey, T.
    Wang, Y.
    James, A.
    Mohseni, M.
    Williams, S.
    VALUE IN HEALTH, 2020, 23 : S231 - S231